Mark Trudeau
CIK 1540412 · President and CEO · last filed 2025-11-14
Mark Trudeau is a President and CEO who has filed 59 SEC Form 4 insider transactions across 3 companies since 2012. The most recent filing, for TEL, was dated Nov 14, 2025. Across all open-market trades the lifetime net is −$7.0M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.5M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
MNK price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
15 HAMPSHIRE STREET
MANSFIELD, MA 02048
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TEL | Director | 7,123 | $207.10 | $1.48M | -$996.7K | 12 | 2025-11-14 |
| Keenova Therapeutics plc (MNK) Delisted | President and CEO | 11,312 | $0.34 | $3.8K | -$6.01M | 38 | 2022-06-21 |
| Covidien plc (COV) Delisted | Senior Vice President | 29,262 | — | — | $0 | 8 | 2013-05-07 |
Recent Filings
59 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-11-14 | TEL | Mixed | +435 | -$95.2K | EDGAR |
| 2024-11-15 | TEL | Mixed | +771 | -$85.2K | EDGAR |
| 2024-04-29 | TEL | Notice (144) | −7,044 | -$987.6K | EDGAR |
| 2024-04-29 | TEL | Sell (S) | −7,044 | -$996.7K | EDGAR |
| 2023-12-14 | TEL | Mixed | +1,143 | -$51.8K | EDGAR |
| 2022-11-16 | TEL | Mixed | +1,281 | -$53.3K | EDGAR |
| 2022-06-21 | Keenova Therapeutics plc (MNK) Delisted | Disp (D) | — | $0 | EDGAR |
| 2021-12-13 | TEL | Mixed | +935 | -$49.0K | EDGAR |
| 2020-11-16 | Keenova Therapeutics plc (MNK) Delisted | Sell (S) | −217,072 | -$27.4K | EDGAR |
| 2020-11-12 | TEL | Mixed | +1,338 | -$47.3K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.